+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dasabuvir"

Hepatitis C Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Thumbnail Image

Hepatitis C Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • March 2024
  • 168 Pages
  • Global
  • 1 Results (Page 1 of 1)
Loading Indicator

Dasabuvir is a direct-acting antiviral drug used to treat chronic hepatitis C virus (HCV) infection. It is a non-structural protein 5A (NS5A) inhibitor, which works by blocking the replication of the virus. Dasabuvir is typically used in combination with other antiviral drugs, such as sofosbuvir and ribavirin, to treat HCV infection. It is approved for use in adults with genotype 1, 2, 3, or 4 HCV infection. Dasabuvir is available in tablet form and is typically taken twice daily with food. Common side effects include headache, nausea, fatigue, and insomnia. Serious side effects include liver damage, anemia, and depression. The dasabuvir market is a subset of the infectious diseases drugs market. It is a rapidly growing market, driven by the increasing prevalence of HCV infection and the development of new treatments. The market is expected to continue to grow in the coming years, as new treatments are developed and more people are diagnosed with HCV infection. Some companies in the dasabuvir market include AbbVie, Gilead Sciences, Merck, and Bristol-Myers Squibb. Show Less Read more